Randomized Phase III Study of Nivolumab and Ipilimumab Versus Carboplatin-Based Doublet in First-Line Treatment of PS 2 or Elderly (≥ 70 Years) Patients with Advanced Non–small Cell Lung Cancer (Energy-Gfpc 06-2015 Study).
Journal of clinical oncology（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要